3rd Circuit Affirms Dismissal Of Testosterone Drug Stock-Drop Class Action
PHILADELPHIA — The Third Circuit U.S. Court of Appeals on Jan. 25 affirmed dismissal of stock-drop lawsuit involving a testosterone replacement therapy drug, finding that the plaintiff’s alleged wrongs against stockholders...To view the full article, register now.
Already a subscriber? Click here to view full article